- RSV (Respiratory Syncytial Virus)
- Contraindications & Precautions (Vaccines and Antibody)
What are the contraindications and precautions to nirsevimab or clesrovimab?
Nirsevimab (Beyfortus, Sanofi) and clesrovimab (Enflonsia, Merck) are contraindicated in persons with a history of severe allergic reactions (e.g., anaphylaxis) after a previous dose of the same product or to a product component. As with any injection, when administering nirsevimab or clesrovimab to children with increased risk for bleeding, providers should follow CDC’s general best practices for immunization of children with bleeding disorders: www.cdc.gov/vaccines/hcp/imz-best-practices/special-situations.html#cdc_report_pub_study_section_8-vaccinating-persons-with-increased-bleeding-risk.
Nirsevimab or clesrovimab administration should be deferred if a child has a moderate or severe acute illness until they have recovered. A mild illness is not a reason to delay an otherwise indicated dose.


